Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.
about
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillationWarfarin: almost 60 years old and still causing problemsManaging anticoagulation for atrial fibrillation: current issues and future strategiesUntreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment optionsAtrial fibrillation and stroke preventionA New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish PopulationComparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort StudyAtrial fibrillation in women: treatmentTRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT).Outcomes of anticoagulation therapy in patients with mental health conditions.[Oral anticoagulation and risk of bleeding in elderly patients - the aspect of polypharmacy].Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study.Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic reviewValidation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testingThe clinical impact of different coagulometers on patient outcomes.Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.A re-appraisal of warfarin control in the treatment of deep vein thrombosis and / or pulmonary embolism.The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes.The future prospects of pharmacogenetics in oral anticoagulation therapy.Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.Computerized clinical decision support systems for therapeutic drug monitoring and dosing: a decision-maker-researcher partnership systematic reviewTo bleed or not to bleed. Is that the question?Using highly variable warfarin dosing to identify patients at risk for adverse events.Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin.Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation.Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation.Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.Major vessel occlusion may predict subtherapeutic anticoagulation intensity and feasibility of administration of intravenous thrombolyticsAnticoagulation control in the peri-hospitalization period.Novel anticoagulants in atrial fibrillation stroke preventionOral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies.Natural history of bleeding and characteristics of early bleeders among warfarin initiators - a cohort study in Finland.Pharmacogenetics of warfarin: current status and future challenges.Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2.Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort stuPolypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trialPotential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation?Genetic variations and their influence on risk and treatment of venous thrombosis.
P2860
Q24197843-01B7B48F-A910-4EFE-AEAD-8F334AD5E8F7Q24678632-588367CB-0E7A-4C2D-9B6F-295B60314AC6Q26991728-B67CEBEE-7EFD-41DE-A7E9-F14F9960364BQ28081837-1D504F5D-035D-4702-99D0-49EADB437907Q28201536-9E9C45FB-ABCD-415C-8C37-BF084F99CAAEQ28550740-49960762-324E-4279-A1C7-CAA3ACDF56FAQ28552407-D9C62985-DC88-4235-9F8E-2015A29CF0CCQ30241862-26D3E3B5-0BA6-4082-A8E0-2EAD971F1AAEQ33582706-D0D86058-E22E-4D6E-AC7D-26385651F657Q33633124-31651BD7-88F4-4BF7-B6F0-D1FB46EA3202Q33635549-F92CD35D-30B2-485C-97E2-8B8485489C19Q33754167-5B460CCC-95CF-4E64-9471-2C13F3ADBD79Q33795571-B89B40DD-3BB4-4E50-ADCD-C2D7AC66258FQ33813830-DC263C03-7436-451F-BA07-B948D9B52ABFQ33848923-F5615F20-E972-4D76-BD0B-F4CB7158B08DQ33891646-635751A8-843D-4247-810F-DF150A4EB18DQ33918677-23F987C5-C3F6-4668-A5B7-40A320FD5B2BQ34200428-FB66A7EC-F0AA-484F-A1BC-27B86DAFCCF6Q34530230-8F5CB8C1-1460-4C97-B08D-9A7A45299B73Q35079761-C97EDACD-C247-4851-AC15-89D58A899FE8Q35206188-992DF4E7-D35E-4A68-97A3-DD87365C552BQ35373575-4CAA7CC3-43F1-4130-A644-1A7EDB9FC7AFQ35415257-40BA1B0A-AE6F-4BA3-92EB-7DC8B40F4C74Q35752573-239CCE15-AB64-4BBA-BDD2-7D8AA5B63FEEQ35771232-310FCA1F-AB22-47CA-977D-7B2611C2470EQ35860841-267146F9-8CC6-47DF-83F3-A3057DAC1EECQ36017218-CE1C45C1-129F-4192-AFBA-25E7CB76FBECQ36087965-89D08238-5AB4-4BC6-A1D5-BD5E3F0C4A68Q36269672-FCEA702B-1B82-495E-97D0-6F2A519BCB53Q36417047-A7A73654-B8C3-44A8-BEEE-9D489D2F7262Q36443814-45BDAB78-88BC-4B3C-9F76-24112098C455Q36567348-5BA6BDA1-36ED-46A2-998C-6B1F241BAC30Q36575256-459D87BF-8878-4AD6-8ED8-0747B59B132AQ36597343-4F4615C7-16A0-4FB5-8841-5C9414EFF815Q36770313-53CAED1B-F4FE-431B-B4B6-C989062CF3D4Q36947797-CF05DCD3-D391-415E-9764-4A6C45582280Q37007416-D9DC6CBF-52F3-4894-A11D-AFED15CBBBD9Q37108889-1E0FF82F-8A5E-4111-AF9F-9C1A2592425AQ37113990-D80971F2-13F7-475D-BC9A-A8B4F74C9921Q37126654-D09C3985-0DAC-4EF0-A91F-7E4B3C85D6D0
P2860
Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Evaluation of the pattern of t ...... in a large British population.
@ast
Evaluation of the pattern of t ...... in a large British population.
@en
type
label
Evaluation of the pattern of t ...... in a large British population.
@ast
Evaluation of the pattern of t ...... in a large British population.
@en
prefLabel
Evaluation of the pattern of t ...... in a large British population.
@ast
Evaluation of the pattern of t ...... in a large British population.
@en
P2093
P2860
P921
P356
P1433
P1476
Evaluation of the pattern of t ...... in a large British population.
@en
P2093
P2860
P304
P356
10.1136/HRT.2004.042465
P407
P577
2005-04-01T00:00:00Z